'A New TNBC Standard Of Care' – Trodelvy Could Vindicate Gilead’s $21bn Buyout
Survival Gains In Third Line Patients
Analysts agree that new Phase III data suggests the antibody-drug conjugate will be a new standard of care in third-line TNBC, with potential in earlier treatment lines and in several other tumor types.
You may also be interested in...
Accounting for nearly a third of the global clinical pipeline, the oncology sector is set to grow to $250bn in sales by 2024 predicts a new report, identifying five research trends driving broad changes. COVID-19 has impacted trials, with 2% having been slowed down, suspended or discontinued.
Public Company Edition: Outside the US, Zai Lab raised more in its recent Hong Kong initial public offering – $766.4m – than PMV, Prelude, Taysha, Graybug and Greenwich combined. Also, Gilead priced debt to fund its $21bn Immunomedics buy and ADC Therapeutics raised $204m.
Tecentriq is the only checkpoint inhibitor to get approval for first-line TNBC but failure in a second study for that indication will encourage rival Merck & Co with Keytruda nearing approval.